Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Helixmith’s Plasmid DNA Therapeutic Moves Forward With New Formulation

Non-Viral Gene Therapy Set For Mass Production

Executive Summary

South Korea's Helixmith reaches a milestone with a US FDA nod to use a new in-house developed formulation for its plasmid DNA therapeutic Engensis, said to be more suited to mass production, in its upcoming Phase III trials for diabetic peripheral neuropathy.

You may also be interested in...



The Race Is On. When Will Korea Have Its Own Approved Gene Therapy?

Scrip takes a look at the landscape of the South Korean gene and cell therapy sector, which is under the spotlight with the implementation of a new cutting-edge biologics law.

Helixmith Mods Engensis Trial Plans As Probe Unravels PK Anomalies

After probing pharmacokinetic data flaws in the first US Phase III study for its gene therapy Engensis, Korea's Helixmith concludes that these stemmed from clinical operation issues. As a result, it admits a failure to meet the primary endpoint but is still moving forward with new trials given signals of efficacy and safety in an extended study.

Korea Regulatory Streamlining Plans Eye Innovation, Commercialization Support

South Korea's drug ministry, together with consumer and business groups, announces a raft of major regulatory innovation tasks it aims to achieve over the next few years, a major goal being to speed up patient access to innovation.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146039

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel